Is that why Aerpio Pharmaceuticals (Nasdaq: ARPO) stock plunged in the AH session?
Aerpio Pharmaceuticals, (Nasdaq: ARPO), the stock dipped -40.89% to $1.33 in the After-market session, as Razuprotafib met its primary efficacy endpoint at 28 days in Aerpio’s double-blind Phase 2 trial in patients with elevated intraocular pressure associated with open-angle glaucoma and ocular hypertension. Compared to the monotherapy group, razuprotafib did not show any statistically significant […]